0J4V Stock Overview
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Heron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.58 |
| 52 Week High | US$3.21 |
| 52 Week Low | US$0.54 |
| Beta | 1.71 |
| 1 Month Change | -6.58% |
| 3 Month Change | 2.72% |
| 1 Year Change | 7.03% |
| 3 Year Change | -85.42% |
| 5 Year Change | -86.26% |
| Change since IPO | -89.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0J4V | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.1% | -0.4% | 2.2% |
| 1Y | 7.0% | -29.1% | 0.9% |
Return vs Industry: 0J4V exceeded the UK Biotechs industry which returned -29.1% over the past year.
Return vs Market: 0J4V exceeded the UK Market which returned 0.9% over the past year.
Price Volatility
| 0J4V volatility | |
|---|---|
| 0J4V Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0J4V has not had significant price volatility in the past 3 months.
Volatility Over Time: 0J4V's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 126 | Craig Collard | www.herontx.com |
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Heron Therapeutics, Inc. Fundamentals Summary
| 0J4V fundamental statistics | |
|---|---|
| Market cap | US$383.42m |
| Earnings (TTM) | -US$110.56m |
| Revenue (TTM) | US$127.04m |
3.0x
P/S Ratio-3.5x
P/E RatioIs 0J4V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0J4V income statement (TTM) | |
|---|---|
| Revenue | US$127.04m |
| Cost of Revenue | US$117.00m |
| Gross Profit | US$10.04m |
| Other Expenses | US$120.60m |
| Earnings | -US$110.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 7.90% |
| Net Profit Margin | -87.02% |
| Debt/Equity Ratio | -511.4% |
How did 0J4V perform over the long term?
See historical performance and comparison